PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): A GINECO, ENGOT, and GCIG study

Alejandra Martinez, Fabrice Lecuru, Nicolò Bizzarri, Cyrus Chargari, Anne Ducassou, Anna Fagotti, Francesco Fanfani, Giovanni Scambia, David Cibula, Berta Díaz-Feijoo, Antonio Gil Moreno, Martina Aida Angeles, Mustafa Zelal Muallem, Christhardt Kohler, Mathieu Luyckx, Frederic Kridelka, Agnieszka Rychlik, K. G. Gerestein, Viola Heinzelmann, Pedro T. RamirezMichael Frumovitz, Gwenael Ferron, Sarah Betrian, Thomas Filleron, Christina Fotopoulou, Denis Querleu

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Background Positron emission tomography/computed tomography (PET/CT) fails to detect approximately 25% of aortic lymph node metastasis in patients with PET/CT stage IIIC1 cervical cancer. Surgical staging could lead to treatment modification and to improved para-aortic and distant control. Primary Objective(s) To demonstrate if chemoradiation with tailored external beam radiation field based on surgical staging and pathologic examination of the para-aortic lymph node is associated with improved 3-year disease-free survival compared with patients staged with PET/CT staging only. Study Hypothesis Surgical staging followed by tailored chemoradiation will improve disease-free survival while avoiding unnecessary prophylactic extended-field chemoradiation in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC1 cervical cancer. Trial Design This is an international multicenter, randomized, phase III study. Eligible patients will be randomized 1:1 between PET/CT staging followed by chemoradiation (control arm), or surgical staging followed by tailored chemo-radiation (experimental arm). Randomization will be stratified by tumor stage according to TNM classification, center, and adjuvant treatment. Major Inclusion/Exclusion Criteria Main inclusion criteria are histologically proven PET/CT FIGO stage IIIC1 cervical cancer. Main exclusion criteria include unequivocal positive common iliac or para-aortic lymph node at pre-therapeutic imaging PET/CT. Primary Endpoint(s) The primary endpoint is disease-free survival defined as the time from randomization until first relapse (local, regional, or distant), or death from any cause. Sample Size 510 eligible patients Estimated Dates for Completing Accrual and Presenting Results The estimated date for completing accrual will be Q2 2027. The estimated date for presenting results will be Q4 2030. Trial Registration Number NCT05581121.

Original languageEnglish (US)
Pages (from-to)293-298
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume33
Issue number2
DOIs
StatePublished - Feb 6 2023

Keywords

  • cervical cancer
  • lymph nodes
  • radiotherapy, intensity-modulated
  • Lymph Nodes/surgery
  • Humans
  • Neoplasm Recurrence, Local/pathology
  • Positron Emission Tomography Computed Tomography
  • Lymphatic Metastasis/pathology
  • Uterine Cervical Neoplasms/surgery
  • Female
  • Retrospective Studies
  • Neoplasm Staging
  • Lymph Node Excision/methods

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Fingerprint

Dive into the research topics of 'PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): A GINECO, ENGOT, and GCIG study'. Together they form a unique fingerprint.

Cite this